Bronstein, Gewirtz & Grossman, LLC Encourages Praxis Precision Medicines, Inc. (PRAX) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Praxis Precision Medicines, Inc. ("Praxis" or "the Company") (NASDAQ:PRAX). Investors who purchased Praxis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PRAX.

Investigation Details

On August 4, 2025, Praxis announced its Q2 2025 financial results. The Company reported mid-stage clinical results from the trial of vormatrigine, an anti-seizure medication. Praxis admitted that more than half of patients experienced treatment-emergent adverse events, with almost 25% of study participants discontinuing the medication. Following this news, Praxis stock price dropped more than 5% on the same day.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Praxis securities, you can assist this investigation by visiting the firm’s site: bgandg.com/PRAX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

comtex tracking

COMTEX_468066352/2457/2025-08-15T11:01:43

Scroll to Top